Clinical Research Directory
Browse clinical research sites, groups, and studies.
Virtue® SAB in the Treatment of Coronary ISR Trial
Sponsor: Orchestra BioMed, Inc
Summary
A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR).
Official title: A Prospective, Multi-center, Single-blind, Randomized (1:1), Non-inferiority Study Comparing Clinical Outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the Treatment of Coronary Artery In-stent Restenosis (ISR).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
740
Start Date
2025-10-20
Completion Date
2032-10
Last Updated
2025-10-29
Healthy Volunteers
No
Conditions
Interventions
Virtue Sirolimus AngioInfusion Balloon
Percutaneous Coronary Intervention
AGENT™ Paclitaxel Drug-Coated Balloon
Percutaneous Coronary Intervention
Locations (2)
St. Francis Hospital
Roslyn, New York, United States
The Lindner Center for Research at Christ Hospital
Cincinnati, Ohio, United States